Successful '9-month Bangladesh regimen' for multidrugresistant tuberculosis among over 500 consecutive patients

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 10, 2014, Pages 1180-1187

  Aung, K J M ^a   Van Deun, A ^b,c   Declercq, E ^d   Sarker, M R ^a   Das, P K ^a   Hossain, M A ^a   Rieder, H L ^c,e  

^a Damien Foundation Bangladesh   (Bangladesh)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^d Damien Foundation   (Belgium)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Multidrug resistance; Standardization; Treatment; Tuberculosis

Indexed keywords

CLOFAZIMINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BANGLADESH; CHILD; DIABETES MELLITUS; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GLUCOSURIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONITORING; MULTIDRUG RESISTANT TUBERCULOSIS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; REINFECTION; RELAPSE; SCHOOL CHILD; SPUTUM SMEAR; TREATMENT OUTCOME; DOSE RESPONSE; DRUG EFFECTS; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; RISK FACTOR; SPUTUM; STATISTICAL MODEL; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BANGLADESH; CHILD; CLOFAZIMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; KANAMYCIN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; PYRAZINAMIDE; RISK FACTORS; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84907020883     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0100     Document Type: Article

References (14)

1. World Health Organization Global tuberculosis report, 2013 WHO/HTM/TB/2013.11 Geneva, Switzerland: WHO, 2013.
2. Van Deun A, Aung K J M, Halim M A, et al Short, highly effective, and inexpensive standardized treatment of multidrugresistant tuberculosis Am J Respir Crit Care Med 2010; 182: 684-692.
3. Salimullah M, Tahera Y, Siddiqui M A, et al Prevalence of human immunodeficiency virus infection among tuberculosis cases in some clinics in Dhaka, Bangladesh Trans R Soc Trop Med Hyg 2000; 94: 276.
4. World Health Organization Guidelines for surveillance of drug resistance in tuberculosis 4th ed WHO/HTM/TB/2009.422 Geneva, Switzerland: WHO, 2009.
5. Hamid Salim A, Aung K J M, HossainMA, Van Deun A.Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB Int J Tuberc Lung Dis 2006; 10: 1248-1254.
6. Kamerbeek J, Schouls L, Kolik A, et al Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagno sis and epidemiology J Clin Microbiol 1997; 35: 907-914
7. Supply P,Allix C,Lesjean S,et al Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-numb er tandem repeat typing of Mycobacterium tuberculosis J Clin Microbiol 2006, 44, 4498-4510.
8. Laserson K F, Thorpe L E, Leimane V, et al Speaking the same language: treatment outcome definition s for multidrug-resistant tuberculosis Int J Tuberc Lung Dis 2005; 9: 640-645.
9. Gumusboga A, Aung K J M, Rigouts L, Van Deun A.Transmission of multidrug-resistant and extensively drugresistant tuberculosis in rural Bangladesh: lessons learnt Public Health Action 2012; 2: 76-78.
10. Peloquin C A, Hadad D J, Molino L P, et al Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis Antimicrob Agents Chemother 2008; 52: 852-857.
11. Grosset J H, Tyagi S, Almeida D V, et al Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice Am J Respir Crit Care Med 2013; 188: 608-612.
12. Pietersen E, Ignatius E, Streicher E M, et al Long-term outcomes of patients with extensively drug-resist ant tuberculosis in South Africa: a cohort study Lancet 2014; 383: 1230-1239.
13. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis 2011 update WHO/HTM/TB/2011.6 Geneva, Switzerland: WHO, 2011.
14. Park-Wyllie L Y, Juurlink D N, Kopp A, et al Outpatient gatifloxacin therapy and dysglycemia in older adults N Engl J Med 2006; 354: 1352-1361.